Market Size of Oral Mucositis Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 0.96 Billion |
| Market Size (2029) | USD 1.36 Billion |
| CAGR (2024 - 2029) | 7.03 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Oral Mucositis Market Analysis
The Oral Mucositis Market size is estimated at USD 0.96 billion in 2024, and is expected to reach USD 1.36 billion by 2029, growing at a CAGR of 7.03% during the forecast period (2024-2029).
The increasing prevalence of cancer, autoimmune diseases, and infections, along with improvements in treatment options and heightened awareness and diagnosis, are anticipated to drive the growth of the oral mucositis market during the forecast period.
Increasing cancer cases and the rising use of chemotherapy and radiotherapy are primary drivers fueling the demand in the oral mucositis market. For instance, according to the October 2023 report of Macmillan Cancer Support, the incidence of cancer in the United Kingdom is increasing rapidly. About 3.5 million people in the United Kingdom are expected to suffer from cancer in 2025, and this number is projected to reach 4 million by 2030. The high number of cancer cases may lead to higher use of cancer treatments like chemotherapy and radiation, which are common causes of oral mucositis. This increases the demand for effective mucositis management solutions, thus bolstering the market growth.
Similarly, as per an article published in Cancer Research and Treatment, in March 2024, about 34,404 new lung cancer cases are expected to be diagnosed in South Korea in 2024, compared to 32,606 lung cancer cases diagnosed in the previous year. Lung cancer patients often undergo chemotherapy and radiation therapy, which can lead to oral mucositis. The increased use of these treatments due to rising lung cancer cases may drive the demand for products that manage and alleviate mucositis symptoms.
Furthermore, the advancements in treatment options for oral mucositis among patients receiving hematopoietic stem cell transplants are further anticipated to boost the market's growth over the forecast period. For instance, according to an article published in Support Care Cancer in August 2023, it was observed that oral cryotherapy is an effective method to prevent oral mucositis (OM) induced by chemotherapeutic agents, such as melphalan (Mel) as well as in allogeneic hematopoietic stem cell transplantation recipients in the cases without methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis. Oral cryotherapy is a valuable treatment option for oral mucositis, and its efficacy in providing symptomatic relief may increase its demand in the market, propelling the market growth.
Therefore, owing to the rising burden of cancer, advancements in treatment options for oral mucositis, and new product launches, the market studied is expected to grow over the forecast period. However, due to the high cost of treatment, limited awareness and diagnosis of oral mucositis, side effects, and limited efficacy of existing treatments, the market is likely to impede over the forecast period.
